(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 76.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Ac Immune Sa's revenue in 2026 is $21,616,049.On average, 6 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,155,103,937, with the lowest ACIU revenue forecast at $1,615,259,659, and the highest ACIU revenue forecast at $2,660,050,629. On average, 6 Wall Street analysts forecast ACIU's revenue for 2027 to be $9,309,312,394, with the lowest ACIU revenue forecast at $0, and the highest ACIU revenue forecast at $28,309,775,776.
In 2028, ACIU is forecast to generate $11,055,310,820 in revenue, with the lowest revenue forecast at $6,780,102,274 and the highest revenue forecast at $18,256,625,931.